Semaglutide tablets and injections: what the evidence says about the differences

What the approval data tells us about oral semaglutide

The MHRA's June 2026 approval of Wegovy tablets was based on the OASIS 4 phase-3 trial, 307 adults with obesity or overweight plus at least one weight-related condition, followed for 64 weeks alongside lifestyle changes. Average weight loss was around 13.6% compared with roughly 2.4% on placebo. Among participants who adhered fully throughout the trial, that figure reached approximately 16.6%. The NHS medicines page for semaglutide covers both the injectable and tablet formulations and is worth reading for a plain-language summary of what each involves.

The weekly injection, by contrast, was evaluated in the STEP 1 trial (68 weeks, 2.4 mg maintenance dose), which recorded around 15% average weight loss versus placebo, a figure cited in NICE technology appraisal TA875. The tablet's 13.6% average and the injection's 15% are close but not directly comparable because the trials differ in duration, population and adherence protocols. If you are weighing up whether semaglutide tablets are better than injections, it is worth understanding why putting too much weight on the gap between those two numbers would be reading more into the data than it justifies.

Our detailed look at how the two forms perform unpacks the trial methodologies side by side for anyone who wants to go further into the evidence.

Absorption: the practical reason the doses look so different

Injections deliver semaglutide subcutaneously (directly into fat tissue under the skin) so absorption is relatively predictable. Oral semaglutide faces a much harder job: the gastrointestinal wall is not designed to absorb peptide molecules, and stomach acid would normally degrade them before they reach the bloodstream. Novo Nordisk solved this by co-formulating the tablet with SNAC, an absorption enhancer that creates a localised alkaline environment around the tablet and briefly increases permeability at a specific region of the stomach lining.

The result is that bioavailability for the oral form is much lower than for the injection, and if you have been wondering whether semaglutide tablets are the same as the injection, this difference in how each is absorbed helps explain why the maintenance dose is 25 mg for the tablet compared with 2.4 mg weekly for the injection. The tablet schedule begins at 1.5 mg once daily, rising through 4 mg and 9 mg to the 25 mg maintenance level, with at least one month at each step. Because even modest food or drink affects absorption substantially, the tablet must be taken first thing in the morning with a small amount of plain water, then nothing else (no coffee, no food, no other oral medicines) for at least 30 minutes.

A quick check worth building into your routine: before you take the tablet, glance at the clock and set a 30-minute reminder on your phone. It takes under a minute and removes the most common reason absorption is compromised.

Storage, travel and the needle question

For many people the most immediately relevant difference is physical. Wegovy injections require refrigeration at 2–8°C; the tablet needs no refrigeration and is stored at room temperature, which makes travel considerably simpler. There is also no injection technique to learn, no need to rotate sites between the abdomen, thigh and upper arm, and no sharps disposal to arrange.

The injection's side-effect profile is well-established over several years of prescribing. The tablet appears to produce a broadly similar GI-led pattern (nausea, vomiting, diarrhoea, constipation) though the OASIS 4 data showed gastrointestinal events in around 74% of the tablet group versus 42% in the placebo arm, described as mostly mild to moderate and transient. Whether that rate reflects the oral route specifically or the newness of the titration approach in that population is still being studied. Our overview of the Wegovy tablet covers the side-effect picture in more detail.

For anyone managing the injection side, the sharps disposal container available through our pharmacy is a practical addition if you're new to injectable treatments.

Eligibility differences and what is not licensed for weight loss

Both forms carry a UK weight-management licence for adults with a BMI of 30 or above, or a BMI of 27–29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or dyslipidaemia. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. One meaningful difference: the dedicated single-dose 7.2 mg weekly pen (approved by the MHRA on 14 April 2026 as a higher-maintenance option for the injection) carries a BMI-30-only licence; that higher dose is not available in the tablet form.

Two products that commonly come up in this conversation are worth separating out clearly. Ozempic (injectable semaglutide, 0.5 mg and 1 mg) and Rybelsus (oral semaglutide, 3 mg, 7 mg and 14 mg) are both licensed in the UK for type 2 diabetes, not for weight management. Rybelsus in particular is sometimes confused with Wegovy tablets because both are oral semaglutide, but the doses are entirely different and the licensed indications are different. A prescriber working to a weight-management indication would prescribe Wegovy, not Rybelsus.

You can read a full guide to choosing between semaglutide tablets or injections, explore the full comparison of semaglutide tablets versus injections, or read about the weight-loss treatments we offer before deciding whether to start a consultation.

Which form suits you depends on your medical history, preferences and how your prescriber weighs the evidence for your specific situation. Start your free consultation and our prescribers will work through the options with you.